General guidance on exploratory and confirmatory subgroup analysis in late-stage clinical trials

被引:32
作者
Dmitrienko, Alex [1 ]
Muysers, Christoph [2 ]
Fritsch, Arno [3 ]
Lipkovich, Ilya
机构
[1] Quintiles, Ctr Stat Drug Dev, 6700 W 115th St, Overland Pk, KS 66209 USA
[2] Bayer HealthCare, Clin Stat, Berlin, Germany
[3] Bayer HealthCare, Clin Stat, Wuppertal, Germany
关键词
Biomarker evaluation; enrichment designs; regulatory guidance; subgroup analysis; subgroup identification; FRACTIONAL POLYNOMIALS; REGULATORY ISSUES; ADAPTIVE DESIGNS; SELECTION; IDENTIFICATION; CONSISTENCY; BIOMARKERS; FRAMEWORK;
D O I
10.1080/10543406.2015.1092033
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This article focuses on a broad class of statistical and clinical considerations related to the assessment of treatment effects across patient subgroups in late-stage clinical trials. This article begins with a comprehensive review of clinical trial literature and regulatory guidelines to help define scientifically sound approaches to evaluating subgroup effects in clinical trials. All commonly used types of subgroup analysis are considered in the article, including different variations of prospectively defined and post-hoc subgroup investigations. In the context of confirmatory subgroup analysis, key design and analysis options are presented, which includes conventional and innovative trial designs that support multi-population tailoring approaches. A detailed summary of exploratory subgroup analysis (with the purpose of either consistency assessment or subgroup identification) is also provided. The article promotes a more disciplined approach to post-hoc subgroup identification and formulates key principles that support reliable evaluation of subgroup effects in this setting.
引用
收藏
页码:71 / 98
页数:28
相关论文
共 66 条
  • [61] A REGULATORY PERSPECTIVE ON ESSENTIAL CONSIDERATIONS IN DESIGN AND ANALYSIS OF SUBGROUPS WHEN CORRECTLY CLASSIFIED
    Wang, Sue-Jane
    Hung, H. M. James
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2014, 24 (01) : 19 - 41
  • [62] Eliciting and using expert opinions about influence of patient characteristics on treatment effects: a Bayesian analysis of the CHARM trials
    White, IR
    Pocock, SJ
    Wang, D
    [J]. STATISTICS IN MEDICINE, 2005, 24 (24) : 3805 - 3821
  • [63] ANALYSIS AND INTERPRETATION OF TREATMENT EFFECTS IN SUBGROUPS OF PATIENTS IN RANDOMIZED CLINICAL-TRIALS
    YUSUF, S
    WITTES, J
    PROBSTFIELD, J
    TYROLER, HA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (01): : 93 - 98
  • [64] A Robust Method for Estimating Optimal Treatment Regimes
    Zhang, Baqun
    Tsiatis, Anastasios A.
    Laber, Eric B.
    Davidian, Marie
    [J]. BIOMETRICS, 2012, 68 (04) : 1010 - 1018
  • [65] Design and Analysis Considerations in Clinical Trials With a Sensitive Subpopulation
    Zhao, Yan D.
    Dmitrienko, Alex
    Tamura, Roy
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2010, 2 (01): : 72 - 83
  • [66] Estimating Individualized Treatment Rules Using Outcome Weighted Learning
    Zhao, Yingqi
    Zeng, Donglin
    Rush, A. John
    Kosorok, Michael R.
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 2012, 107 (499) : 1106 - 1118